Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: PHG stock price vs INCY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Implied fair value · at PHG's multiple
Needs PHG P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PHG FY 2025 (ended Dec 31, 2025) · INCY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 61% equity / 39% debt · EV / Revenue 1.94x · EV / EBITDA 29.13x
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
PHG carries the larger enterprise value at $40.12B against $23.73B; PHG trades on the lower EV / Revenue multiple (1.94x vs 4.62x); INCY on the lower EV / EBITDA (13.50x vs 29.13x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
KONINKLIJKE PHILIPS NV · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.29x
Net debt / EBITDA
Leverage against operating earnings
11.03x
-0.90x
Cash and equivalents
Liquid reserves on the balance sheet
$2.79B
$3.10B
Total debt
Interest-bearing obligations outstanding
$15.86B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
GE HealthCare Technologies Inc.
PHG vs GEHC
HOLOGIC INC
PHG vs HOLX
BOSTON SCIENTIFIC CORP
PHG vs BSX
INTUITIVE SURGICAL INC
PHG vs ISRG
ZIMMER BIOMET HOLDINGS, INC.
PHG vs ZBH
AMGEN INC
PHG vs AMGN
GILEAD SCIENCES, INC.
PHG vs GILD
VERTEX PHARMACEUTICALS INC / MA
PHG vs VRTX
REGENERON PHARMACEUTICALS, INC.
PHG vs REGN
BIOGEN INC.
PHG vs BIIB
$1.51B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
